Original language | English |
---|---|
Pages (from-to) | 5-9 |
Number of pages | 5 |
Journal | Pharmacoeconomics |
Volume | 42 |
Issue number | 1 |
Early online date | 5 Oct 2023 |
DOIs |
|
Publication status | Published - 1 Jan 2024 |
Bibliographical note
Funding Information:This project was commissioned by the National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Programme (Grant number: NIHR132004). See the HTA programme website for further project information ( https://www.nihr.ac.uk/explore-nihr/funding-programmes/health-technology-assessment.htm ). This summary of the EAG report was compiled after NICE issued recommendations for the Cancer Drug Fund (CDF). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the NICE, NIHR or Department of Health and Social Care.
Keywords
- Humans
- Trastuzumab/therapeutic use
- Camptothecin
- Immunoconjugates
- Technology Assessment, Biomedical
- Cost-Benefit Analysis
- Receptor, ErbB-2